The invention relates to chemical-based methods and products for mitigating the impact of an oil spill, that act via mechanisms which include reducing adhesiveness, herding, thickening and gelling. N-fatty acid amino acid (FA-AA) conjugates display oil-herding behavior when formulated as a salt, or the free acid in water-miscible organic solvents. Various salts of FA-AA conjugates are water soluble and can herd oils and increase the thickness of the oil layer. Replacement of the acid group of fatty acid α-amino acid conjugates with other groups that act as hydrogen bond donors and acceptors results in potent phase selective organo gellants. The oil thickeners or gellants include can be prepared from biobased feedstocks, have low toxicity, high capacity for oil and reduction of the need to use an organic solvent to apply the thickener or gellant to an oil and water mixture in order to gel the oil phase. ##STR00001##

A pharmaceutical composition, comprising a therapeutically effective amount of an active pharmaceutical ingredient (API) compound represented by the following structural formula ##STR00001## at least one acidifying agent; and a vehicle base comprising at least one pharmaceutically acceptable non-aqueous solvent. Values and preferred values of the variables in structural formula (I) are defined herein.

A pharmaceutical composition, comprising a therapeutically effective amount of an active pharmaceutical ingredient (API) compound represented by the following structural formula ##STR00001## at least one acidifying agent; and a vehicle base comprising at least one pharmaceutically acceptable non-aqueous solvent. Values and preferred values of the variables in structural formula (I) are defined herein.

This disclosure is related to aromatic compounds of formula (I), and methods of their use in treating medical conditions associated with Heat Shock Protein-90 (HSP90), e.g., cancer. Compounds of formula (I) have the following structure: ##STR00001##
Also disclosed are pharmaceutical compositions comprising compounds of formula (I).

This invention relates to photoswitchable inhibitors of histone deacetylases and methods of using the same.

This invention relates to photoswitchable inhibitors of histone deacetylases and methods of using the same.

The present disclosure relates to substituted hydroxystilbene compounds and derivatives, specifically 2-substituted hydroxystilbene compounds and derivatives, the synthesis of such compounds and their use in therapy.

Provided are compounds that inhibit ferroptosis activity, or modulate or inhibit a disease associated with ferroptosis dysregulation, such as neuropathy, ischemia reperfusion injury, acute kidney failure and cancer, including corresponding sulfonamides, and pharmaceutically acceptable salts, hydrates and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof with an effective amount of the compound or composition, and detecting a resultant improvement in the person's health or condition.

The present invention relates to novel “reverse amide” compounds comprising a zinc chelator group, and the use of such compounds in the inhibition of HDAC6 and in the treatment of various diseases, disorders or conditions related to HDAC6.

The present invention relates to novel “reverse amide” compounds comprising a zinc chelator group, and the use of such compounds in the inhibition of HDAC6 and in the treatment of various diseases, disorders or conditions related to HDAC6.